These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome. Taja-Chayeb L; Vidal-Millán S; Gutiérrez-Hernández O; Trejo-Becerril C; Pérez-Cárdenas E; Chávez-Blanco A; de la Cruz-Hernández E; Dueñas-González A World J Surg Oncol; 2009 Dec; 7():97. PubMed ID: 20017945 [TBL] [Abstract][Full Text] [Related]
23. Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts. Burt EC; James LA; Greaves MJ; Birch JM; Boyle JM; Varley JM Br J Cancer; 2000 Aug; 83(4):467-72. PubMed ID: 10945493 [TBL] [Abstract][Full Text] [Related]
25. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. Xian W; Miron A; Roh M; Semmel DR; Yassin Y; Garber J; Oliva E; Goodman A; Mehra K; Berkowitz RS; Crum CP; Quade BJ J Pathol; 2010 Jan; 220(1):17-23. PubMed ID: 19834951 [TBL] [Abstract][Full Text] [Related]
26. Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation. Yamazaki F; Shima H; Osumi T; Narumi S; Kuroda T; Shimada H J Pediatr Hematol Oncol; 2018 Apr; 40(3):e195-e197. PubMed ID: 28902083 [TBL] [Abstract][Full Text] [Related]
27. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family. Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585 [TBL] [Abstract][Full Text] [Related]
28. p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome. Debelenko LV; Perez-Atayde AR; Dubois SG; Grier HE; Pai SY; Shamberger RC; Kozakewich HP Pediatr Dev Pathol; 2010; 13(3):218-24. PubMed ID: 20028212 [TBL] [Abstract][Full Text] [Related]
29. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes. Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481 [TBL] [Abstract][Full Text] [Related]
30. Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. Rieber J; Remke M; Hartmann C; Korshunov A; Burkhardt B; Sturm D; Mechtersheimer G; Wittmann A; Greil J; Blattmann C; Witt O; Behnisch W; Halatsch ME; Orakcioglu B; von Deimling A; Lichter P; Kulozik A; Pfister S Genes Chromosomes Cancer; 2009 Jul; 48(7):558-68. PubMed ID: 19378321 [TBL] [Abstract][Full Text] [Related]
31. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome. Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881 [TBL] [Abstract][Full Text] [Related]
32. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982 [TBL] [Abstract][Full Text] [Related]
33. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Wu CC; Shete S; Amos CI; Strong LC Cancer Res; 2006 Aug; 66(16):8287-92. PubMed ID: 16912210 [TBL] [Abstract][Full Text] [Related]
34. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome. Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965 [TBL] [Abstract][Full Text] [Related]
35. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile. Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001 [TBL] [Abstract][Full Text] [Related]
36. A novel TP53 splicing mutation in a Li-Fraumeni syndrome family: a patient with Wilms' tumour is not a mutation carrier. Varley JM; McGown G; Thorncroft M; White GR; Tricker KJ; Kelsey AM; Birch JM; Evans DG Br J Cancer; 1998 Oct; 78(8):1081-3. PubMed ID: 9792154 [TBL] [Abstract][Full Text] [Related]
37. A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Law JC; Strong LC; Chidambaram A; Ferrell RE Cancer Res; 1991 Dec; 51(23 Pt 1):6385-7. PubMed ID: 1933902 [TBL] [Abstract][Full Text] [Related]
38. The first documentation of Li-Fraumeni syndrome in Korea. Bang YJ; Kang SH; Kim TY; Jung CW; Oh SM; Choe KJ; Kim NK J Korean Med Sci; 1995 Jun; 10(3):205-10. PubMed ID: 8527048 [TBL] [Abstract][Full Text] [Related]
39. Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. Schiffman JD; Chun N; Fisher PG; Dahl GV; Ford JM; Eggerding FA Pediatr Blood Cancer; 2008 Apr; 50(4):914-6. PubMed ID: 17554785 [TBL] [Abstract][Full Text] [Related]
40. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]